#Amrn conversations update#
We assume no obligation to update these statements as circumstances change.
#Amrn conversations trial#
Examples of such statements include, but are not limited to, our current expectations regarding our commercial and financial performance, including levels of VASCEPA prescription, VASCEPA product and licensing revenues, costs, gross margin and other commercial metrics our current plans and expectations regarding spending, including expenditures for promotion of VASCEPA and for purchases of additional supply of VASCEPA our current expectations regarding the adequacy of our financial resources our current plans and expectations for product revenue growth, sales force productivity and product promotion in light of COVID-19 and the potential for adding attention to cardiovascular risk reduction drugs like VASCEPA as a result of COVID-19 our current plans and expectations related to patent litigation and expectations related to the potential launch of generic versions of VASCEPA by generic companies and by ourself our current expectations on the substance and timing of VASCEPA regulatory reviews outside of the United States our current plans and expectations regarding the timing, scope and success of international expansion, including expectations regarding our ability to launch VASCEPA in Europe and expectations in China for clinical trial results and potential to bridge REDUCE-IT results and labeling and promotion of VASCEPA through our partner in China our current plans and expectations regarding VASCEPA exclusivity outside of the United States, including Europe and China our current plans for commercial expansion in the United States with the entry of current and potential future generic competition and our current plans and expectations regarding the clinical study of VASCEPA related to COVID-19. Please be aware that this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided by the Private Securities Litigation Reform Act. Before we begin, let me turn to our forward-looking statement. Thank you, operator, and thank you to everyone for joining our fourth quarter and full-year 2020 results. I would like to turn the conference call over to Alina Doubrovna, associate manager of investor relations at Amarin.Īlina Doubrovna - Associate Manager of Investor Relations This conference call is being recorded today, February 25, 2021. Welcome to Amarin Corporation's conference call to discuss its fourth quarter and full-year 2020 financial results and operational updates.
0 kommentar(er)
